An update on HDV: Virology, pathogenesis and treatment

Antiviral Therapy

Volumn 18, Issue 3 PARTB, 2013, Pages 541-548

  Alvarado Mora, Mónica V ^a   Locarnini, Stephen ^b   Rizzetto, Mario ^c   Rebello Pinho, João R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; HEPATITIS DELTA ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERON; PEGINTERFERON ALPHA; PROTEIN ARGININE METHYLTRANSFERASE; TENOFOVIR;

ANTIBODY TITER; CANCER RISK; DELTA AGENT HEPATITIS; DISEASE COURSE; GENOTYPE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; INFECTION; LIFE CYCLE STAGE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MIXED INFECTION; MONOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RNA RNA HYBRIDIZATION; SUMOYLATION; VIREMIA; VIRUS CLASSIFICATION; VIRUS LOAD; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS TRANSMISSION;

COINFECTION; GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS D; HEPATITIS DELTA ANTIGENS; HEPATITIS DELTA VIRUS; HUMANS; LIVER TRANSPLANTATION; PHYLOGENY; RNA, VIRAL; SATELLITE VIRUSES; VIRUS REPLICATION;

EID: 84879665710     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2598     Document Type: Review

References (69)

1. Rizzetto M, Canese MG, Arico S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977; 18:997-1003.
2. Rizzetto M, Canese MG, Gerin JL, London WT, Sly DL, Purcell RH. Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis 1980; 141:590-602.
3. Rizzetto M, Hoyer B, Canese MG, Shih JW, Purcell RH, Gerin JL. Delta agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A 1980; 77:6124-6128.
4. Chen PJ, Kalpana G, Goldberg J, et al. Structure and replication of the genome of the hepatitis delta virus. Proc Natl Acad Sci U S A 1986; 83:8774-8778.
5. Elena SF, Dopazo J, Flores R, Diener TO, Moya A. Phylogeny of viroids, viroidlike satellite RNAs, and the viroidlike domain of hepatitis delta virus RNA. Proc Natl Acad Sci U S A 1991; 88:5631-5634.
6. Mayo MA. Current ideas about the taxonomy of sub-viral virus-like agents. Prog Clin Biol Res 1993; 382:117-124.
7. Abou-Jaoudé G, Sureau C. Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange. J Virol 2007; 81:13057-13066.
8. Kuo M Y, Sharmeen L, Dinter-Gottlieb G, Taylor J. Characterization of self-cleaving RNA sequences on the genome and antigenome of human hepatitis delta virus. J Virol 1988; 62:4439-4444.
9. Hampel A, Tritz R. RNA catalytic properties of the minimum (-)sTRSV sequence. Biochemistry 1989; 28:4929-4933.
10. Flores R, Grubb D, Elleuch A, Nohales MA, Delgado S, Gago S. Rolling-circle replication of viroids, viroid-like satellite RNAs and hepatitis delta virus: variations on a theme. RNA Biol 2011; 8:200-206.
11. Webb CH, Luptak A. HDV-like self-cleaving ribozymes. RNA Biol 2011; 8:719-727.
12. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011; 378:73-85.
13. Bonino F, Hoyer B, Ford E, Shih JW, Purcell RH, Gerin JL. The delta agent: HBsAg particles with delta antigen and RNA in the serum of an HBV carrier. Hepatology 1981; 1:127-131.
14. Taylor JM. Hepatitis delta virus: cis and trans functions required for replication. Cell 1990; 61:371-373.
15. Wang KS, Choo QL, Weiner AJ, et al. Structure, sequence and expression of the hepatitis delta (delta) viral genome. Nature 1986; 323:508-514.
16. Robertson HD. How did replicating and coding RNAs first get together? Science 1996; 274:66-67.
17. Brazas R, Ganem D. A cellular homolog of hepatitis delta antigen: implications for viral replication and evolution. Science 1996; 274:90-94.
18. Taylor J, Pelchat M. Origin of hepatitis delta virus. Future Microbiol 2010; 5:393-402.
19. Polson AG, Bass BL, Casey JL. RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase. Nature 1996; 380:454-456.
20. Luo GX, Chao M, Hsieh SY, Sureau C, Nishikura K, Taylor J. A specific base transition occurs on replicating hepatitis delta virus RNA. J Virol 1990; 64:1021-1027.
21. Chao M, Hsieh SY, Taylor J. The antigen of hepatitis delta virus: examination of in vitro RNA-binding specificity. J Virol 1991; 65:4057-4062.
22. Lee CZ, Lin JH, Chao M, McKnight K, Lai MM. RNA-binding activity of hepatitis delta antigen involves two arginine-rich motifs and is required for hepatitis delta virus RNA replication. J Virol 1993; 67:2221-2227.
23. Xia YP, Yeh CT, Ou JH, Lai MM. Characterization of nuclear targeting signal of hepatitis delta antigen: nuclear transport as a protein complex. J Virol 1992; 66:914-921.
24. Rozzelle JE, Jr., Wang JG, Wagner DS, Erickson BW, Lemon SM. Self-association of a synthetic peptide from the N terminus of the hepatitis delta virus protein into an immunoreactive alpha-helical multimer. Proc Natl Acad Sci U S A 1995; 92:382-386.
25. Glenn JS, Watson JA, Havel CM, White JM. Identification of a prenylation site in delta virus large antigen. Science 1992; 256:1331-1333.
26. Tseng CH, Cheng TS, Shu CY, Jeng KS, Lai MM. Modification of small hepatitis delta virus antigen by SUMO protein. J Virol 2010; 84:918-927.
27. Ryu WS, Bayer M, Taylor J. Assembly of hepatitis delta virus particles. J Virol 1992; 66:2310-2315.
28. Nath N, Mushahwar IK, Fang CT, Berberian H, Dodd RY. Antibodies to delta antigen in asymptomatic hepatitis B surface antigen-reactive blood donors in the United States and their association with other markers of hepatitis B virus. Am J Epidemiol 1985; 122:218-225.
29. Weisfuse IB, Hadler SC, Fields HA, et al. Delta hepatitis in homosexual men in the United States. Hepatology 1989; 9:872-874.
30. Casey JL, Brown TL, Colan EJ, Wignall FS, Gerin JL. A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci U S A 1993; 90:9016-9020.
31. Lee CM, Changchien CS, Chung JC, Liaw YF. Characterization of a new genotype II hepatitis delta virus from Taiwan. J Med Virol 1996; 49:145-154.
32. Alvarado-Mora MV, Romano CM, Gomes-Gouvea MS, Gutierrez MF, Carrilho FJ, Pinho JR. Dynamics of hepatitis D (delta) virus genotype 3 in the Amazon region of South America. Infect Genet Evol 2011; 11:1462-1468.
33. Gomes-Gouvêa MS, Pereira Soares Mdo C, Guedes de Carvalho Mello IM, et al. Hepatitis D and B virus genotypes in chronically infected patients from the Eastern Amazon basin. Acta Trop 2008; 106:149-155.
34. Gomes-Gouvêa MS, Soares MC, Bensabath G, et al. Hepatitis B virus and hepatitis delta virus genotypes in outbreaks of fulminant hepatitis (Labrea black fever) in the western Brazilian Amazon region. J Gen Virol 2009; 90:2638-2643.
35. Dény P. Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades? Curr Top Microbiol Immunol 2006; 307:151-171.
36. Barros LM, Gomes-Gouvêa MS, Pinho JR, et al. Hepatitis delta virus genotype 8 infection in northeast Brazil: inheritance from African slaves? Virus Res 2011; 160:333-339.
37. Eigen M, Biebricker CK. Sequence space and quasispecies distribution. In Domingo E, Holland JJ, Ahlquist P (Editors). RNA genetics. Boca Raton: CRC Press, 1998; pp. 211-245.
38. Krushkal J, Li WH. Substitution rates in hepatitis delta virus. J Mol Evol 1995; 41:721-726.
39. Farci P. Delta hepatitis: an update. J Hepatol 2003; 39 Suppl 1:S212-S219.
40. Smedile A, Lavarini C, Crivelli O, Raimondo G, Fassone M, Rizzetto M. Radioimmunoassay detection of IgM antibodies to the HBV-associated delta (d) antigen; clinical significance in d infection. J Med Virol 1982; 9:131-138.
41. Aragona M, Macagno S, Caredda F, et al. Serological response to the hepatitis delta virus in hepatitis D. Lancet 1987; 329:478-480.
42. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat 2010; 17:749-756.
43. Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European concerted action on viral hepatitis. Gut 2000; 46:420-426.
44. Abbas Z, Qureshi M, Hamid S, Jafri W. Hepatocellular carcinoma in hepatitis D: does it differ from hepatitis B monoinfection? Saudi J Gastroenterol 2012; 18:18-22.
45. Ji J, Sundquist K, Sundquist J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. J Natl Cancer Inst 2012; 104:790-792.
46. Popper H, Thung SN, Gerber MA, et al. Histologic studies of severe delta agent infection in Venezuelan Indians. Hepatology 1983; 3:906-912.
47. Sakugawa H, Nakasone H, Nakayoshi T, et al. Hepatitis delta virus genotype II b predominates in an endemic area, Okinawa, Japan. J Med Virol 1999; 58:366-372.
48. Niro GA, Smedile A, Andriulli A, Rizzetto M, Gerin JL, Casey JL. The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology 1997; 25:728-734.
49. Buitrago B, Popper H, Hadler SC, et al. Specific histologic features of Santa Marta hepatitis: a severe form of hepatitis delta-virus infection in northern South America. Hepatology 1986; 6:1285-1291.
50. Denniston KJ, Hoyer BH, Smedile A, Wells F V, Nelson J, Gerin JL. Cloned fragment of the hepatitis delta virus RNA genome: sequence and diagnostic application. Science 1986; 232:873-875.
51. Smedile A, Niro MG, Rizzetto M. Detection of serum HDV-RNA by RT-PCR. In Hamatake RK, Lau JYN (Editors). NJ Methods in Molecular Medicine, vol 95: Hepatitis B and D protocols. Totowa: Humana Press Inc 2004; pp. 85-93.
52. Yamashiro T, Nagayama K, Enomoto N, et al. Quantitation of the level of hepatitis delta virus RNA in serum, by real-time polymerase chain reaction - and its possible correlation with the clinical stage of liver disease. J Infect Dis 2004; 189:1151-1157.
53. Le Gal F, Gordien E, Affolabi D, et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol 2005; 43:2363-2369.
54. Scholtes C, Icard V, Amiri M, et al. Standardized one-step real-time reverse transcription-PCR assay for universal detection and quantification of hepatitis delta virus (HDV) from clinical samples in the presence of a heterologous internal control RNA. J Clin Microbiol 2012;50:2126-2128.
55. Ferns RB, Nastouli E, Garson JA. Quantitation of hepatitis delta virus using a single-step internally controlled realtime RT-qPCR and a full-length genomic RNA calibration standard. J Virol Methods 2012; 179:189-194.
56. Niro GA, Gioffreda D, Fontana R. Hepatitis delta virus infection: open issues. Digest Liver Dis 2011; 43 Suppl 1:S19-S24.
57. Erhardt A, Gerlich W, Starke C, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006; 26:805-810.
58. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or incombination with ribavirin in chronic hepatitis delta. Hepatology 2006; 44:713-720.
59. Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44:728-735.
60. Niro GA, Ciancio A, Tillman HL, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 2005; 22:227-232.
61. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364:322-331.
62. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat 2010; 17:749-756.
63. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7:31-40.
64. Mederacke I, Filmann N, Yurdaydin C, et al. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. J Hepatol 2012; 56:115-122.
65. Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011; 55:1121-1131.
66. Brichler S, Setshedi M, Renou C. Treatment of hepatitis delta chronic infection: HBs antigen quantification may help monitoring, and HBs antigen seroconversion could be the ideal 'end' point of treatment. J Clin Virol 2012; 55:83-84.
67. Yurdaydin C, Kabacam G, Cakaloglu Y, et al. Efficacy of pegylated interferon-based treatment in patients with cirrhosis due to chronic delta hepatitis: comparison with non-cirrhotic patients. Hepatology 2009; 50 Suppl 4:736A.
68. Castelnau C, Le Gal F, Ripault M P, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44:728-735.
69. Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine interferon vs interferon. J Viral Hepat 2008; 15:314-321. Estado de São Paulo Estado de São Paulo